{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:36:09Z","timestamp":1788381369239,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The availability of biological therapies has helped achieve clinical remission (CR) in patients with severe asthma (SA). Scientific societies issued different definitions of remission, with the common denominator of the suspension of systemic corticosteroids for at least 1\u00a0year. Additional criteria are associated with symptoms, stability of pulmonary function, disease exacerbations, ACT \u226520 or \u226523, and ACQ \u22641.5. We evaluated the agreement among criteria adopted in Italy, Spain, Germany, Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      An observational prospective, single-center study was carried out: 65 patients with SA treated for 12 or 24\u00a0months with omalizumab, mepolizumab, benralizumab or dupilumab were recruited. Data on exacerbations, need of systemic corticosteroids, asthma symptoms, ACT and ACQ, pulmonary function at baseline and 12 and 24\u00a0months were collected. Differences of qualitative variables were assessed with the Chi-squared or Fisher\u2019s exact test. Cohen\u2019s Kappa coefficients were calculated to assess agreement between definitions of remission. The statistical significance threshold was set at\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05. Data analysis was carried out using STATA version 17.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>28 (43.1%) patients at 12 months and 27 (47.4%) at 24 months did not meet any criteria for CR, whereas 34 (52.3%) at 12\u00a0months and 28 (49.1%) at 24\u00a0months met at least one definition of complete CR. The agreement among the selected guidelines was substantial, with an overall Fleiss K of 0.7971 (P &amp;lt; 0.0001). Chronic rhinosinusitis with nasal polyps was more prevalent in patients who achieved CR, whereas gastro-esophageal reflux disease was more prevalent in patients who did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Consistently with other studies only 52.3% at 12 months and 49.1% at 24\u00a0months achieved complete CR. The agreement of CR is substantial. The main limitations of the study are its monocentric nature and the poor sample size, whereas its main strengths were the evaluation both at 12 and 24\u00a0months and the adoption of four different definitions. Nonetheless, a worldwide definition could enhance the standardization of CR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1776527","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:50:32Z","timestamp":1773298232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the concordance of asthma remission definitions according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma"],"prefix":"10.3389","volume":"17","author":[{"given":"A. G.","family":"Ledda","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Canalis","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Puci","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari","place":["Sassari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sambugaro","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Taurisano","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Piano","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bullita","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sotgiu","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari","place":["Sassari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Firinu","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Del Giacco","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thorax.58.suppl_1.1i","article-title":"Chapters 1-3","volume":"58","year":"2003","journal-title":"Thorax"},{"key":"B1","doi-asserted-by":"publisher","first-page":"190137","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"107720","DOI":"10.1016\/j.rmed.2024.107720","article-title":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world cohort study","volume":"231","author":"Bult","year":"2024","journal-title":"Respir. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"210183","DOI":"10.1183\/16000617.0183-2021","article-title":"Holy grail: the journey towards disease modification in asthma","volume":"31","author":"Busse","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"16250","DOI":"10.20452\/pamw.16250","article-title":"Asthma and comorbidities: recent advances","volume":"132","author":"Cazzola","year":"2022","journal-title":"Pol. Arch. Intern Med."},{"key":"B6","doi-asserted-by":"crossref","first-page":"PA2495","DOI":"10.1183\/13993003.congress-2018.PA2495","article-title":"Asthma and obstructive sleep Apnea Syndrome (OSAS)","volume-title":"Sleep and control of breathing","author":"Chaouki","year":"2018"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100365","DOI":"10.1016\/j.jacig.2024.100365","article-title":"On-treatment clinical remission of severe asthma with real-world longer-term biologic use","volume":"4","author":"Chipps","year":"2025","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"B8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.rmed.2016.09.014","article-title":"The asthma-anxiety connection","volume":"120","author":"Del Giacco","year":"2016","journal-title":"Respir. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12325-022-02307-x","article-title":"A review of Anti-IL-5 therapies for eosinophilic granulomatosis with polyangiitis","volume":"40","author":"Koike","year":"2023","journal-title":"Adv. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1080\/02770903.2020.1784194","article-title":"How does comorbid bronchiectasis affect asthmatic patients? A meta-analysis","volume":"58","author":"Lan","year":"2021","journal-title":"J. Asthma"},{"key":"B12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1037\/0022-006X.70.3.691","article-title":"Psychological aspects of asthma","volume":"70","author":"Lehrer","year":"2002","journal-title":"J. Consult Clin. Psychol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1055\/a-2070-2135","article-title":"S2k-Leitlinie zur fach\u00e4rztlichen Diagnostik und Therapie von Asthma 2023","volume":"77","author":"Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"key":"B14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaip.2024.01.020","article-title":"Treatable traits in asthma: the importance of extrapulmonary Traits\u2014GERD, CRSwNP, atopic dermatitis, and depression\/anxiety","volume":"12","author":"McDonald","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with Benralizumab","volume":"39","author":"Menzies-Gow","year":"","journal-title":"Adv. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"","journal-title":"J. Asthma Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/alr.21609","article-title":"Asthma: definitions and pathophysiology","volume":"5","author":"Mims","year":"2015","journal-title":"Int. Forum Allergy Rhinol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.alit.2023.02.006","article-title":"Executive summary: japanese guidelines for adult asthma (JGL) 2021","volume":"72","author":"Niimi","year":"2023","journal-title":"Allergol. Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1150162","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab induces long-term On-Treatment clinical remission in patients with type 2 asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/resp.14767","article-title":"Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis","volume":"29","author":"Pelaia","year":"2024","journal-title":"Respirology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100277","DOI":"10.1016\/j.opresp.2023.100277","article-title":"GEMA 5.3. Spanish guideline on the management of asthma","volume":"5","author":"Plaza Moral","year":"2023","journal-title":"Open Respir. Arch."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2147\/JAA.S321212","article-title":"Association between a type 2 inflammatory disease burden score and outcomes among patients with asthma","volume":"14","author":"Price","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MCP.0000000000000640","article-title":"The impact of comorbidities on severe asthma","volume":"26","author":"Rogliani","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","article-title":"Analysis of comorbidities and multimorbidity in adult patients in the international severe asthma registry","volume":"132","author":"Scelo","year":"2024","journal-title":"Ann. Allergy, Asthma & Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/jpm13061020","article-title":"Clinical asthma remission obtained with biologics in real life: patients\u2019 prevalence and characteristics","volume":"13","author":"Sposato","year":"2023","journal-title":"J. Pers. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"B31","unstructured":"World health organization\n          \n          \n          2025"},{"key":"B32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/bjo.53.6.361","article-title":"Posterior subcapsular cataracts and glaucoma associated with long-term oral corticosteroid therapy. In patients with rheumatoid arthritis and related conditions","volume":"53","author":"Williamson","year":"1969","journal-title":"Br. J. Ophthalmol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1776527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:50:36Z","timestamp":1773298236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1776527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1776527"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1776527","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1776527"}}